Clinical trials: Disease Prevention
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least…
- Trial name
- NCT01054456
- Testing
- palonesetron
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eisai Inc.
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy infants.
- Trial name
- NCT00262002
- Testing
- MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation), MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation), MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Gastroesophageal Reflux
ASTERIX: Low Dose ASA and Nexium
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
- Trial name
- NCT00251966
- Testing
- Esomeprazole
- Where
- 94 sites in Australia, Bulgaria and 9 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca
Antibiotics Associated Colitis, Pulmonary Infection
Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotic-Associated Diarrhea (AAD) is a common complication of antibiotic use. The frequency of AAD can be high (26 - 60%) or moderate (13-29%) during hospital outbreaks and is relatively infrequent in outpatients.
- Trial name
- NCT01058356
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Pharmbio Korea Co., Ltd.
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Neoplasms, Diarrhea
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Currently there is an ongoing clinical trial for patients with chemotherapy induced diarrhea. This trial is being conducted to evaluate the efficacy of two dose levels (30 mg and 40 mg) of an investigational drug in reducing the…
- Trial name
- NCT00050635
- Testing
- Sandostatin LAR Depot
- Where
- 34 sites in United States
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
In individuals with obesity, the optimal dosing and duration of venous thromboembolism (VTE) prophylaxis in settings representing acute medical illness or surgery is limited due to lack of randomized controlled trials (RCTs)…
- Trial name
- NCT05819125
- Where
- United States
- Volunteers
- 21,000 people
- Sponsor
- Sanofi
Migraine
A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM.
- Trial name
- NCT00475514
- Testing
- Frovatriptan 2.5mg QD, Frovatriptan 2.5 mg BID
- Volunteers
- 500 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Breast Neoplasm
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).
- Trial name
- NCT00736333
- Testing
- Pegylated Liposomal Doxorubicin
- Volunteers
- 167 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thrombosis, Pulmonary Embolism
Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis
This study evaluates whether treatment with rosuvastatin on top of standard anti-coagulant treatment will decrease the risk of recurrent venous thromboembolism and arterial thromboembolic events in patients with previous deep…
- Trial name
- Du Lac (NCT01164540)
- Testing
- Rosuvastatin (AZD4522)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT00108758
- Testing
- activated recombinant human factor VII
- Where
- 37 sites in United States, Argentina and 10 more
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
covid19
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable…
- Trial name
- NCT04435314
- Testing
- Nitazoxanide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Atopic Dermatitis, Infant, Newborn
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12th month of life by applying the SanaCutan Basiscreme.
- Trial name
- MOPAD (NCT04398758)
- Testing
- SanaCutan Basiscreme
- Where
- 10 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Thrombosis, Deep Vein, Pulmonary Embolism
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
- Trial name
- NCT03812835
- Sponsor
- Pfizer
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Opioid Dependence
A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
This phase 4 study will evaluate the feasibility of initiating subjects on VIVITROL in prison and continuing VIVITROL upon release into the community.
- Trial name
- NCT01453374
- Testing
- VIVITROL 380mg
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Alkermes, Inc.
Pulmonary Embolism, Deep Vein Thrombosis
SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur.
- Trial name
- NCT00071279
- Testing
- SR34006 (idraparinux sodium) Injection
- Where
- 65 sites in United States, Australia and 18 more
- Volunteers
- 1,215 people
- Sponsor
- Sanofi
Crohn's Disease
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
This study aims to compare azathioprine versus mesalazine tablets for the prevention of clinical relapse in postoperative Crohn's disease (CD) patients with moderate or severe endoscopic recurrence.
- Trial name
- NCT00946946
- Testing
- Azathioprine, Mesalazine
- Where
- 2 sites in Austria, Germany
- Volunteers
- 78 people
- Sponsor
- Dr. Falk Pharma GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.